Relay rises as combo breast cancer therapy cuts disease progression in early study

Relay Therapeutics

09/09/2024 13:29

** Shares of drug developer Relay Therapeutics  RLAY.O  rise
14.58% to $7.15 premarket 
    ** Co says its experimental breast cancer treatment 
meaningfully extended the time patients lived without their
disease worsening in an early-stage trial   
    ** The therapy helped 52 patients live for an average of 9.2
months without the disease worsening after treatment in the
study
     ** Co to start a late-stage trial for the combination next
year, pending regulatory discussions
    ** The treatment, RLY-2608, in combination with
AstraZeneca's  AZN.L  Faslodex, was generally well tolerated
across all doses, the company said
    ** The trial enrolled 118 heavily pre-treated patients with
PI3K mutant, advanced breast cancer
    ** Up to last close, stock down 43.3% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))